Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.
Journal: Journal of hepatology
Published: January 27, 2025
Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
Journal: The oncologist
Published: November 26, 2024
Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Journal: Cancer chemotherapy and pharmacology
Published: June 13, 2024
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
Journal: The lancet. Gastroenterology & hepatology
Published: January 10, 2024
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: October 17, 2023
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Journal: Future oncology (London, England)
Published: September 25, 2023
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
Journal: NEJM evidence
Published: August 01, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026